Global University Venturing

The SoftBank-backed round could give the China-based ride hailing company the financial base it needs to compete internationally, where it may well use its CVC investments to forge a path.

Robin Knight, co-founder of In-Part, responds to an earlier GUV editorial that looked at university-industry collaboration and finds much to celebrate.

A round up of all the latest news on www.globaluniversityventuring.com for our subscribers.

British Columbia University has signed a licensing agreement with Commonsense for a treatment of asthma and other allergic conditions.

Boehringer Ingelheim Venture Fund has co-led a $21.8m round for ImCheck Therapeutics, established with the support of Satt Sud-Est.

Virolock Technologies was spun out of Penn State to commercialise a portable device that boosts early detection of viral infections.

Cambridge Enterprise and Cambridge Innovation Capital both participated in the funding round, which is based on research at the Cambridge Institute for Medical Research.

Sosei will pay $45m for a 25% stake in RNA therapy developer Mina Therapeutics and could buy the NTNU spinout outright for about $180m more.

Exploiting research conducted at Navarra University and Harvard Medical School, Vivet Therapeutics is working on gene therapies for metabolic diseases.